Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Maria Ignez Freitas Melro BRAGHIROLI"'
Publikováno v:
Surgical and Experimental Pathology, Vol 7, Iss 1, Pp 1-12 (2024)
Abstract Gastric cancer is the fifth most common cause of cancer-related deaths globally, with a decreasing but still high number of cases. Although there have been improvements in treatment choices, the expected survival rates have not yet been achi
Externí odkaz:
https://doaj.org/article/6fe4ad88e3db487f80fdf73a768387f3
Autor:
Aline Lopes CHAGAS, Angelo Alves de MATTOS, Flair José CARRILHO, Paulo Lisboa BITTENCOURT, Denise Cerqueira Paranaguá VEZOZZO, Natally HORVAT, Manoel de Souza ROCHA, Venâncio Avancini Ferreira ALVES, Gabriela Perdomo CORAL, Mario Reis ALVARES-DA-SILVA, Fabio Marinho do Rego BARROS, Marcos Roberto MENEZES, Lucas Moretti MONSIGNORE, Fabricio Ferreira COELHO, Renato Ferreira da SILVA, Rita de Cássia Martins Alves SILVA, Ilka de Fatima Santana Ferreira BOIN, Luiz Augusto Carneiro D`ALBUQUERQUE, José Huygens Parente GARCIA, Guilherme Eduardo Gonçalves FELGA, Airton Mota MOREIRA, Maria Ignez Freitas Melro BRAGHIROLI, Paulo Marcelo Gehm HOFF, Vivianne Barretto de MELLO, Mariana Fonseca DOTTORI, Tiago Pugliese BRANCO, Leonardo de Lucca SCHIAVON, Thaisa de Fátima Almeida COSTA
Publikováno v:
Arquivos de Gastroenterologia, Vol 57, Iss suppl 1, Pp 1-20 (2020)
ABSTRACT Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related mortality worldwide. The Brazilian Society of Hepatology (SBH) published in 2015 its first recommendations about the management of HCC. Since then, new data have e
Externí odkaz:
https://doaj.org/article/440b2325ee2748338789d49ba4ef2842
Autor:
Leonardo Gomes da Fonseca, Guilherme Nader Marta, Maria Ignez Freitas Melro Braghiroli, Aline Lopes Chagas, Flair Jose Carrilho, Paulo Marcelo Hoff, Jorge Sabbaga
Publikováno v:
BMC Cancer, Vol 18, Iss 1, Pp 1-7 (2018)
Abstract Background Before the targeted therapies era, cytotoxic chemotherapy (CCT) was an option for advanced hepatocellular carcinoma (HCC), even with the lack of supporting evidence. Since the last decade, sorafenib has been established as the fir
Externí odkaz:
https://doaj.org/article/f651009f98cb4a878e3cf8f6ed6aeb2f
Autor:
Angelica Nogueira-Rodrigues, Ronniel Morais Albuquerque, Renan Orsati Clara, Ana Gelatti, Augusto Cesar de Andrade Mota, Bruno Pacheco Pereira, Daniela Dornelles Rosa, Igor Alexandre Protzner Morbeck, Maria Fátima Gaui, Maria Ignez Freitas Melro-Braghiroli, Rafael Aliosha Kaliks, Rodrigo Ramella Munhoz, Sandro Roberto de Araújo Cavalléro, Vladmir Cláudio Cordeiro-de-Lima, Clarissa Maria de Cerqueira Mathias
Publikováno v:
Brazilian Journal of Oncology, Vol 16, Iss (2020)
Background and Objective: Cancer is expected to be the leading cause of death in Brazil by 2030. This scenario demands that health professionals, especially physicians, should be able to implement primary prevention, early detection and cancer patien
Externí odkaz:
https://doaj.org/article/af124495a96649bca6fc4b38aa9db766
Autor:
Ken Kato, Jaffer A. Ajani, Yuichiro Doki, Jianming Xu, Lucjan Wyrwicz, Satoru Motoyama, Takashi Ogata, Hisato Kawakami, Chih-Hung Hsu, Antoine Adenis, Farid El Hajbi, Maria Di Bartolomeo, Maria Ignez Freitas Melro Braghiroli, Eva Holtved, Mariela A. Blum Murphy, Apurva Patel, Nan Hu, Yasuhiro Matsumura, Ian Chau, Yuko Kitagawa
Publikováno v:
Journal of Clinical Oncology. 41:290-290
290 Background: NIVO + chemo and NIVO + IPI demonstrated superior overall survival (OS) vs chemo in CheckMate 648 (NCT03143153), leading to approvals in the US, EU, Japan, and other countries. We report longer follow-up results. Methods: Adults with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0b5d63143a7ea65a76d07f8728559423
https://doi.org/10.1200/jco.2023.41.4_suppl.290
https://doi.org/10.1200/jco.2023.41.4_suppl.290
Autor:
Ian Chau, Jaffer A. Ajani, Yuichiro Doki, Jianming Xu, Lucjan Wyrwicz, Satoru Motoyama, Takashi Ogata, Hisato Kawakami, Chih-Hung Hsu, Antoine Adenis, Farid El Hajbi, Maria Di Bartolomeo, Maria Ignez Freitas Melro Braghiroli, Eva Holtved, Mariela A. Blum Murphy, Sandzhar Abdullaev, Samira Soleymani, Ming Lei, Ken Kato, Yuko Kitagawa
Publikováno v:
Journal of Clinical Oncology. 40:4035-4035
4035 Background: NIVO + chemo and NIVO + IPI demonstrated significant overall survival (OS) benefit vs chemo in previously untreated patients (pts) with advanced ESCC in the phase 3 CheckMate 648 study. We report expanded results from the primary ana
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::66b8aca464308035beb09c10969a9d6f
https://doi.org/10.1200/jco.2022.40.16_suppl.4035
https://doi.org/10.1200/jco.2022.40.16_suppl.4035
Autor:
Sarah Mendes Bezerra, Marisa Riscalla Madi, Aline Lauda Freitas Chaves, Maria Ignez Freitas Melro-Braghiroli, Paulo Marcelo Gehm Hoff, Carlos Gil Ferreira, Lucas Pondaco Bonanno, Gustavo Andrade Pimenta Leite
Publikováno v:
Brazilian Journal of Oncology, Vol 20, Iss (2024)
Cancer remains a significant public health challenge in Brazil, with an estimated 704 thousand new cases annually. Clinical oncology, a pivotal specialty in cancer diagnosis and treatment, has evolved since its formal establishment in 1946. Recent re
Externí odkaz:
https://doaj.org/article/937d84d5014141318bb3c516886a0ec4